Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allurion Technologies, Inc. Common Stock (NY: ALUR )

7.950 -2.480 (-23.78%)
Official Closing Price Updated: 7:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allurion Technologies, Inc. Common Stock

< Previous 1 2 3 4 Next >
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Allurion Expands Virtual Care Suite to the United States
From Allurion Technologies, Inc.
Via Business Wire
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q4 2023
ALUR stock results show that Allurion Technologies beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
From Allurion Technologies, Inc.
Via Business Wire
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
From Allurion Technologies, Inc.
Via Business Wire
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024
From Allurion Technologies, Inc.
Via Business Wire
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Allurion to Participate in Cowen’s 44th Annual Health Care Conference
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
From Allurion Technologies, Inc.
Via Business Wire
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
From Allurion Technologies, Inc.
Via Business Wire
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities
From Allurion Technologies, Inc.
Via Business Wire
Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey
Novo Nordisk's Wegovy has been linked to greater weight loss with prolonged use, with 40% of patients still using the drug a year later. This adherence rate is three times higher than other... 
Via Benzinga
Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook
From Allurion Technologies, Inc.
Via Business Wire
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
From Allurion Technologies, Inc.
Via Business Wire
12 Consumer Discretionary Stocks Moving In Monday's Intraday Session
Via Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Participate in the Jefferies London Healthcare Conference
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023
From Allurion Technologies, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.